A detailed history of Woodline Partners LP transactions in Arbutus Biopharma Corp stock. As of the latest transaction made, Woodline Partners LP holds 668,153 shares of ABUS stock, worth $2.14 Million. This represents 0.02% of its overall portfolio holdings.

Number of Shares
668,153
Previous 926,534 27.89%
Holding current value
$2.14 Million
Previous $2.86 Million 10.13%
% of portfolio
0.02%
Previous 0.03%

Shares

10 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q3 2024

Nov 14, 2024

SELL
$3.12 - $4.56 $806,148 - $1.18 Million
-258,381 Reduced 27.89%
668,153 $2.57 Million
Q2 2024

Aug 14, 2024

SELL
$2.52 - $3.63 $7.92 Million - $11.4 Million
-3,144,125 Reduced 77.24%
926,534 $2.86 Million
Q1 2024

May 15, 2024

SELL
$2.26 - $2.92 $1.47 Million - $1.9 Million
-649,244 Reduced 13.76%
4,070,659 $10.5 Million
Q3 2023

Nov 14, 2023

BUY
$1.9 - $2.27 $4.28 Million - $5.11 Million
2,250,706 Added 91.15%
4,719,903 $9.58 Million
Q2 2023

Aug 14, 2023

SELL
$2.24 - $3.06 $422,033 - $576,528
-188,408 Reduced 7.09%
2,469,197 $5.68 Million
Q1 2023

May 15, 2023

BUY
$2.23 - $3.1 $5.93 Million - $8.24 Million
2,657,605 New
2,657,605 $8.05 Million
Q4 2021

Feb 14, 2022

SELL
$3.11 - $4.61 $1.54 Million - $2.29 Million
-496,172 Closed
0 $0
Q3 2021

Nov 15, 2021

BUY
$2.65 - $4.62 $1.31 Million - $2.29 Million
496,172 New
496,172 $2.13 Million
Q2 2021

Aug 16, 2021

SELL
$2.5 - $3.51 $195,847 - $274,969
-78,339 Closed
0 $0
Q1 2021

May 17, 2021

BUY
$3.14 - $4.84 $245,984 - $379,160
78,339 New
78,339 $261,000

Others Institutions Holding ABUS

About Arbutus Biopharma Corp


  • Ticker ABUS
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 149,951,008
  • Market Cap $481M
  • Description
  • Arbutus Biopharma Corporation, a biopharmaceutical company, develops novel therapeutics for chronic Hepatitis B virus (HBV) infection, SARS-CoV-2, and other coronaviruses in the United States. Its HBV product pipeline consists of AB-729, a proprietary subcutaneously delivered RNA interference product candidate, which in Phase Ia/Ib clinical tria...
More about ABUS
Track This Portfolio

Track Woodline Partners LP Portfolio

Follow Woodline Partners LP and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Woodline Partners LP, based on Form 13F filings with the SEC.

News

Stay updated on Woodline Partners LP with notifications on news.